Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva Pharma, Oasis Pharmaceutic

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Alcoholic Fatty Liver Disease pipeline constitutes 110+ key companies continuously working towards developing 160+ Non-Alcoholic Fatty Liver Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Fatty Liver Disease Market.

The Non-Alcoholic Fatty Liver Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report: https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Non-Alcoholic Fatty Liver Disease treatment therapies with a considerable amount of success over the years.
• Non-Alcoholic Fatty Liver Disease companies working in the treatment market are MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others, are developing therapies for the Non-Alcoholic Fatty Liver Disease treatment
• Emerging Non-Alcoholic Fatty Liver Disease therapies in the different phases of clinical trials are- MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others are expected to have a significant impact on the Non-Alcoholic Fatty Liver Disease market in the coming years.
• In August 2022, Madrigal Pharmaceuticals, Inc. has commenced a clinical trial named "MAESTRO-NASH OUTCOMES," a randomized, double-blind, placebo-controlled Phase 3 study. The trial aims to assess the impact of Resmetirom on liver-related outcomes in individuals diagnosed with well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis. This multi-national, multicenter study involves a double-blind, randomized approach with a placebo control, focusing on participants with well-compensated NASH cirrhosis.
• In July 2022, AstraZeneca has commenced a trial named "A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study" to assess the safety and effectiveness of Cotadutide in individuals diagnosed with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis. The primary objective is to evaluate the safety and efficacy of Cotadutide in participants with non-cirrhotic NASH with fibrosis. The trial, currently underway with 54 participants, is expected to conclude by April 2024.

Non-Alcoholic Fatty Liver Disease Overview
Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition characterized by the accumulation of fat in the liver cells, not caused by excessive alcohol consumption. It encompasses a spectrum of liver disorders ranging from simple fatty liver (steatosis) to more severe conditions like non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis.

Get a Free Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Non-Alcoholic Fatty Liver Disease Drugs Under Different Phases of Clinical Development Include:
• MN-001: MediciNova
• LY3885125: Eli Lilly and Company
• AZD7503: AstraZeneca
• Lanifibranor: Inventiva Pharma
• OA-235i: Oasis Pharmaceuticals, LLC
• Resmetirom: Madrigal Pharmaceuticals, Inc.
• BMN 255: BioMarin Pharmaceutical
• GSK4532990: GlaxoSmithKline
• Saroglitazar Magnesium 4 mg Tablet: Zydus Therapeutics Inc.
• Efruxifermin: Akero Therapeutics, Inc
• PF-06865571: Pfizer
• BI 3006337: Boehringer Ingelheim
• DD01: Neuraly, Inc.
• Efinopegdutide: Merck Sharp & Dohme LLC
• HU6: Rivus Pharmaceuticals, Inc.
• Rencofilstat: Hepion Pharmaceuticals, Inc.

Non-Alcoholic Fatty Liver Disease Route of Administration
Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Non-Alcoholic Fatty Liver Disease Molecule Type
Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics Assessment
• Non-Alcoholic Fatty Liver Disease Assessment by Product Type
• Non-Alcoholic Fatty Liver Disease By Stage and Product Type
• Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration
• Non-Alcoholic Fatty Liver Disease By Stage and Route of Administration
• Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type
• Non-Alcoholic Fatty Liver Disease by Stage and Molecule Type
DelveInsight's Non-Alcoholic Fatty Liver Disease Report covers around 160+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Alcoholic Fatty Liver Disease product details are provided in the report. Download the Non-Alcoholic Fatty Liver Disease pipeline report to learn more about the emerging Non-Alcoholic Fatty Liver Disease therapies at:
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Non-Alcoholic Fatty Liver Disease Therapeutics Market include:
Key companies developing therapies for Non-Alcoholic Fatty Liver Disease are - Eli Lilly and Company, Pfizer, Boehringer Ingelheim, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., MediciNova, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Hepion Pharmaceuticals, Inc., and others.

Non-Alcoholic Fatty Liver Disease Pipeline Analysis:
The Non-Alcoholic Fatty Liver Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease Treatment.
• Non-Alcoholic Fatty Liver Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease drugs and therapies-
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Alcoholic Fatty Liver Disease Pipeline Market Drivers
• Rise in prevalence of NAFLD, large number of drugs are currently being evaluated, growing Research and Development Activities are some of the important factors that are fueling the Non-Alcoholic Fatty Liver Disease Market.

Non-Alcoholic Fatty Liver Disease Pipeline Market Barriers
• However, lack of effective strategies for the prevention and effective treatment of NAFLD, relying on biopsies makes NASH diagnosis a difficult task and other factors are creating obstacles in the Non-Alcoholic Fatty Liver Disease Market growth.

Scope of Non-Alcoholic Fatty Liver Disease Pipeline Drug Insight
• Coverage: Global
• Key Non-Alcoholic Fatty Liver Disease Companies: MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others
• Key Non-Alcoholic Fatty Liver Disease Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others
• Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
• Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers

Request for Sample PDF Report for Non-Alcoholic Fatty Liver Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Non-Alcoholic Fatty Liver Disease Report Introduction
2. Non-Alcoholic Fatty Liver Disease Executive Summary
3. Non-Alcoholic Fatty Liver Disease Overview
4. Non-Alcoholic Fatty Liver Disease- Analytical Perspective In-depth Commercial Assessment
5. Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics
6. Non-Alcoholic Fatty Liver Disease Late Stage Products (Phase II/III)
7. Non-Alcoholic Fatty Liver Disease Mid Stage Products (Phase II)
8. Non-Alcoholic Fatty Liver Disease Early Stage Products (Phase I)
9. Non-Alcoholic Fatty Liver Disease Preclinical Stage Products
10. Non-Alcoholic Fatty Liver Disease Therapeutics Assessment
11. Non-Alcoholic Fatty Liver Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Alcoholic Fatty Liver Disease Key Companies
14. Non-Alcoholic Fatty Liver Disease Key Products
15. Non-Alcoholic Fatty Liver Disease Unmet Needs
16 . Non-Alcoholic Fatty Liver Disease Market Drivers and Barriers
17. Non-Alcoholic Fatty Liver Disease Future Perspectives and Conclusion
18. Non-Alcoholic Fatty Liver Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Non-Alcoholic Fatty Liver Disease Market https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Non-Alcoholic Fatty Liver Disease Epidemiology https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Alcoholic Fatty Liver Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.